General Information
Version
9.1
Revision date
2023-06-07
Product name
LOSARTAN FOR SYSTEM SUITABILITY
CAS No.
114798-26-4
REACH No
A
Emergency telephone
800-424-9300, +1-703- 527-3887
Icons in SDS
Company Information
company name
Sigma-Aldrich Inc
GHS Information
Signal word
Danger
Hazard Codes
Hazard statements (CLP)
H317, H360FD, H362
Hazard statements
Code
Statements
H317
May cause an allergic skin reaction
Section 2
SECTION 2: Hazards identification
Regulation (EC) No. 1272/2008 Classification of the substance or mixture
Signal word
Danger Danger
Hazard statements
H317 May cause an allergic skin reaction. H360FD May damage fertility. May damage the unborn child. H362 May cause harm to breast-fed children. H362 May cause harm to breast-fed children. H317 May cause an allergic skin reaction. H360FD May damage fertility. May damage the unborn child.
Precautionary statements
P202 Do not handle until all safety precautions have been read and understood. P260 Do not breathe dust. P263 Avoid contact during pregnancy and while nursing. P280 Wear protective gloves/ protective clothing/ eye protection/ face protection. P302 + P352 IF ON SKIN: Wash with plenty of water. P308 + P313 IF exposed or concerned: Get medical advice/ attention. P202 Do not handle until all safety precautions have been read and understood. P280 Wear protective gloves/ protective clothing/ eye protection/ face protection. P302 + P352 IF ON SKIN: Wash with plenty of water. P308 + P313 IF exposed or concerned: Get medical advice/ attention.
Supplemental label elements
none Reduced Labeling (<= 125 ml) none
Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher
2.1 Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008 Skin sensitization (Category 1), H317 Reproductive toxicity (Category 1B), H360FD Effects on or via lactation, H362 For the full text of the H-Statements mentioned in this Section, see Section 16.